Last reviewed · How we verify
SEVELAMER
At a glance
| Generic name | SEVELAMER |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
Common side effects
- Vomiting
- Nausea
- Diarrhea
- Dyspepsia
- Peritonitis
- Flatulence
- Constipation
- Abdominal pain
- Pruritus
- Abdominal distension
- Fatigue
- Anorexia
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia (PHASE3)
- A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia (PHASE3)
- AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia (PHASE3)
- FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease (PHASE3)
- Activated Charcoal Use in Chronic Kidney Disease Patients (PHASE2)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEVELAMER CI brief — competitive landscape report
- SEVELAMER updates RSS · CI watch RSS